RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an announcement.
RemeGen Co., Ltd. announced the nomination of Mr. Wen Qingkai as a candidate for the position of executive director and member of the strategy committee, pending approval at the upcoming extraordinary general meeting. Mr. Wen, who has extensive experience in capital operations and corporate governance, currently oversees financing activities and internal controls at RemeGen. His appointment is expected to strengthen the company’s strategic direction and operational oversight.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on the biopharmaceutical industry. The company is involved in the development and commercialization of innovative drugs, with a market focus on addressing unmet medical needs.
YTD Price Performance: 8.89%
Average Trading Volume: 2,364,601
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$14.88B
See more insights into 9995 stock on TipRanks’ Stock Analysis page.